ENPP_APLCA
ID ENPP_APLCA Reviewed; 837 AA.
AC Q95P23;
DT 01-JUL-2008, integrated into UniProtKB/Swiss-Prot.
DT 01-DEC-2001, sequence version 1.
DT 25-MAY-2022, entry version 37.
DE RecName: Full=Enterin neuropeptides;
DE Contains:
DE RecName: Full=ENa;
DE Contains:
DE RecName: Full=ENb;
DE Contains:
DE RecName: Full=ENc;
DE Contains:
DE RecName: Full=ENd;
DE Contains:
DE RecName: Full=ENe;
DE Contains:
DE RecName: Full=ENf;
DE Contains:
DE RecName: Full=ENg;
DE Contains:
DE RecName: Full=ENh;
DE Contains:
DE RecName: Full=ENi;
DE Contains:
DE RecName: Full=ENj;
DE Contains:
DE RecName: Full=ENk;
DE Contains:
DE RecName: Full=ENl;
DE Contains:
DE RecName: Full=ENm;
DE Contains:
DE RecName: Full=ENn;
DE Contains:
DE RecName: Full=ENo;
DE Contains:
DE RecName: Full=ENp;
DE Contains:
DE RecName: Full=ENq;
DE Contains:
DE RecName: Full=ENr;
DE Contains:
DE RecName: Full=ENs;
DE Contains:
DE RecName: Full=ENt;
DE Flags: Precursor;
GN Name=ENPP;
OS Aplysia californica (California sea hare).
OC Eukaryota; Metazoa; Spiralia; Lophotrochozoa; Mollusca; Gastropoda;
OC Heterobranchia; Euthyneura; Tectipleura; Aplysiida; Aplysioidea;
OC Aplysiidae; Aplysia.
OX NCBI_TaxID=6500;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, PROTEOLYTIC
RP PROCESSING, PYROGLUTAMATE FORMATION AT GLU-598; GLN-641; GLN-653; GLN-677;
RP GLN-701; GLN-713 AND GLN-725, AMIDATION AT VAL-57; VAL-146; LEU-190;
RP VAL-211; VAL-244; VAL-276; VAL-297; VAL-336; VAL-348; VAL-360; VAL-372;
RP VAL-384; VAL-396; VAL-408; VAL-420; VAL-432; VAL-444; VAL-456; VAL-468;
RP VAL-480; VAL-492; VAL-504; VAL-516; VAL-528; VAL-540; VAL-606; LEU-637;
RP VAL-649; VAL-661; VAL-673; VAL-685; VAL-697; VAL-709; VAL-721 AND VAL-733,
RP AND MASS SPECTROMETRY.
RC TISSUE=CNS, and Gut;
RX PubMed=11588196; DOI=10.1523/jneurosci.21-20-08247.2001;
RA Furukawa Y., Nakamaru K., Wakayama H., Fujisawa Y., Minakata H., Ohta S.,
RA Morishita F., Matsushima O., Li L., Romanova E., Sweedler J.V., Park J.H.,
RA Romero A., Cropper E.C., Dembrow N.C., Jing J., Weiss K.R., Vilim F.S.;
RT "The enterins: a novel family of neuropeptides isolated from the enteric
RT nervous system and CNS of Aplysia.";
RL J. Neurosci. 21:8247-8261(2001).
CC -!- FUNCTION: Reduce interneurons B4/5 activity. May play a regulatory role
CC in nonfeeding behaviors. {ECO:0000269|PubMed:11588196}.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: High expression in gut and CNS.
CC {ECO:0000269|PubMed:11588196}.
CC -!- MASS SPECTROMETRY: [ENa]: Mass=1145.61; Mass_error=0.03; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENb]: Mass=1019.48; Mass_error=0.01; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENc]: Mass=1174.63; Mass_error=0.02; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENd]: Mass=1132.58; Mass_error=0.03; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENe]: Mass=1091.53; Mass_error=0.01; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENf]: Mass=1169.65; Mass_error=0.01; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENg]: Mass=1152.56; Mass_error=0.04; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENh]: Mass=990.48; Mass_error=0.00; Method=MALDI;
CC Note=ENh.; Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENi]: Mass=1004.49; Mass_error=0.00; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENj]: Mass=992.47; Mass_error=0.01; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENk]: Mass=962.46; Mass_error=0.01; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENl]: Mass=1102.56; Mass_error=0.02; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENl]: Mass=1084.53; Mass_error=0.02; Method=MALDI;
CC Note=ENl'.; Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENm]: Mass=1021.50; Mass_error=0.02; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENo]: Mass=1002.45; Mass_error=0.02; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENp]: Mass=974.50; Mass_error=0.02; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENq]: Mass=1030.47; Mass_error=0.03; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENr]: Mass=1001.45; Mass_error=0.01; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENs]: Mass=986.47; Mass_error=0.00; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC -!- MASS SPECTROMETRY: [ENt]: Mass=1014.48; Mass_error=0.02; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:11588196};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY040526; AAL17716.1; -; mRNA.
DR RefSeq; NP_001191483.1; NM_001204554.1.
DR AlphaFoldDB; Q95P23; -.
DR GeneID; 100533242; -.
DR CTD; 100533242; -.
DR OrthoDB; 1765093at2759; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0007218; P:neuropeptide signaling pathway; IEA:UniProtKB-KW.
PE 1: Evidence at protein level;
KW Amidation; Cleavage on pair of basic residues; Neuropeptide;
KW Pyrrolidone carboxylic acid; Secreted; Signal.
FT SIGNAL 1..25
FT /evidence="ECO:0000255"
FT PROPEP 26..47
FT /evidence="ECO:0000255"
FT /id="PRO_0000343362"
FT PEPTIDE 48..57
FT /note="ENa"
FT /id="PRO_0000343363"
FT PROPEP 61..134
FT /id="PRO_0000343364"
FT PEPTIDE 137..146
FT /note="ENb"
FT /id="PRO_0000343365"
FT PROPEP 150..178
FT /id="PRO_0000343366"
FT PEPTIDE 181..190
FT /note="ENc"
FT /id="PRO_0000343367"
FT PROPEP 194..201
FT /id="PRO_0000343368"
FT PEPTIDE 202..211
FT /note="ENd"
FT /id="PRO_0000343369"
FT PROPEP 215..234
FT /id="PRO_0000343370"
FT PEPTIDE 235..244
FT /note="ENe"
FT /id="PRO_0000343371"
FT PROPEP 248..266
FT /id="PRO_0000343372"
FT PEPTIDE 267..276
FT /note="ENf"
FT /id="PRO_0000343373"
FT PROPEP 280..285
FT /id="PRO_0000343374"
FT PEPTIDE 288..297
FT /note="ENg"
FT /id="PRO_0000343375"
FT PROPEP 301..325
FT /id="PRO_0000343376"
FT PEPTIDE 328..336
FT /note="ENh"
FT /id="PRO_0000343377"
FT PEPTIDE 340..348
FT /note="ENi"
FT /id="PRO_0000343378"
FT PEPTIDE 352..360
FT /note="ENj"
FT /id="PRO_0000343379"
FT PEPTIDE 364..372
FT /note="ENh"
FT /id="PRO_0000343380"
FT PEPTIDE 376..384
FT /note="ENh"
FT /id="PRO_0000343381"
FT PEPTIDE 388..396
FT /note="ENh"
FT /id="PRO_0000343382"
FT PEPTIDE 400..408
FT /note="ENh"
FT /id="PRO_0000343383"
FT PEPTIDE 412..420
FT /note="ENh"
FT /id="PRO_0000343384"
FT PEPTIDE 424..432
FT /note="ENj"
FT /id="PRO_0000343385"
FT PEPTIDE 436..444
FT /note="ENk"
FT /id="PRO_0000343386"
FT PEPTIDE 448..456
FT /note="ENj"
FT /id="PRO_0000343387"
FT PEPTIDE 460..468
FT /note="ENk"
FT /id="PRO_0000343388"
FT PEPTIDE 472..480
FT /note="ENk"
FT /id="PRO_0000343389"
FT PEPTIDE 484..492
FT /note="ENk"
FT /id="PRO_0000343390"
FT PEPTIDE 496..504
FT /note="ENh"
FT /id="PRO_0000343391"
FT PEPTIDE 508..516
FT /note="ENk"
FT /id="PRO_0000343392"
FT PEPTIDE 520..528
FT /note="ENh"
FT /id="PRO_0000343393"
FT PEPTIDE 532..540
FT /note="ENk"
FT /id="PRO_0000343394"
FT PROPEP 544..595
FT /id="PRO_0000343395"
FT PEPTIDE 598..606
FT /note="ENl"
FT /id="PRO_0000343396"
FT PROPEP 610..627
FT /id="PRO_0000343397"
FT PEPTIDE 628..637
FT /note="ENm"
FT /id="PRO_0000343398"
FT PEPTIDE 641..649
FT /note="ENn"
FT /id="PRO_0000343399"
FT PEPTIDE 653..661
FT /note="ENo"
FT /id="PRO_0000343400"
FT PEPTIDE 665..673
FT /note="ENp"
FT /id="PRO_0000343401"
FT PEPTIDE 677..685
FT /note="ENq"
FT /id="PRO_0000343402"
FT PEPTIDE 689..697
FT /note="ENr"
FT /id="PRO_0000343403"
FT PEPTIDE 701..709
FT /note="ENs"
FT /id="PRO_0000343404"
FT PEPTIDE 713..721
FT /note="ENt"
FT /id="PRO_0000343405"
FT PEPTIDE 725..733
FT /note="ENs"
FT /id="PRO_0000439542"
FT PROPEP 734..837
FT /id="PRO_0000343406"
FT REGION 567..594
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 772..837
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 567..583
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 788..805
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 57
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 146
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 190
FT /note="Leucine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 211
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 244
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 276
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 297
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 336
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 348
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 360
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 372
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 384
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 396
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 408
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 420
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 432
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 444
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 456
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 468
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 480
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 492
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 504
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 516
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 528
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 540
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 598
FT /note="Pyrrolidone carboxylic acid (Glu); in form ENl'"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 606
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 637
FT /note="Leucine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 641
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 649
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 653
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 661
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 673
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 677
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 685
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 697
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 701
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 709
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 713
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 721
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 725
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:11588196"
FT MOD_RES 733
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:11588196"
SQ SEQUENCE 837 AA; 92963 MW; B16E1E57000A705D CRC64;
MAKHDVTVMT LLLVVCALHV FDAQGTDVKL NDGFLRSGIM NIPFQRRVSP KYGHNFVGKR
SGFQSPVSPS DYFIPDELND EDESPNMDTY ALFRELLGEY PSSELSDDDV IRPYPVVPWA
WDRFENKRFS KENEKRGSPG FSHSFVGKRM DLSALEKELI AKLKAADLLS PLETEAPGKR
RLPSYGHSFL GKRMPVDVFP RAIPSYSHNF VGKRSGNGEN YFDDLDTFGD ISQRADLGFT
HSFVGKRGNT DFSRNPLARL SQVQNRAIPN FVHKFVGKRS VHNIVKRSSP FYGHNFVGKR
DFEDASEGLD EEEGDIDGYS DDLDVKRVPG YSHSFVGKRI PGYSHSFVGK RTPGYSHSFV
GKRVPGYSHS FVGKRVPGYS HSFVGKRVPG YSHSFVGKRV PGYSHSFVGK RVPGYSHSFV
GKRTPGYSHS FVGKRAPGYS HSFVGKRTPG YSHSFVGKRA PGYSHSFVGK RAPGYSHSFV
GKRAPGYSHS FVGKRVPGYS HSFVGKRAPG YSHSFVGKRV PGYSHSFVGK RAPGYSHSFV
GKRELGEDEI NFLKEVDAAD ISRQLAEEDE KEAMVSVDDK ETLSNEEDAS EDDFEKRELN
FQHAFVGKKD EEGDMGVEME EEMESEKGQP GYGNAFLGKR QPSYGHSFVG KRQPGYSHSF
VGKRVPSFGH SFVGKRQPSY THAFVGKRDP GFNHAFVGKR QPSFGHSFVG KRQPSFTHAF
VGKRQPSFGH SFVGKRSGAE DIDNTFTDNF VVKGSDPLED VLDFYSDSQL IGQPAAANEE
ELQQEAAEES ENQTGTKQLD DKSNVPASSL GDDLPSPVSL SKQEDAEDSH IMATSST
